Alterations of intestinal barrier and microbiota in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 30, Issue 6, 2015, Pages 924-933

  Sabatino, Alice ^a   Regolisti, Giuseppe ^a   Brusasco, Irene ^a   Cabassi, Aderville ^a   Morabito, Santo ^a   Fiaccadori, Enrico ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

chronic kidney disease; endotoxin; inflammation; intestinal microbiota; uraemic toxicity

Indexed keywords

ENDOTOXIN; PREBIOTIC AGENT; PROBIOTIC AGENT;

BACTERIAL METABOLISM; BACTERIAL TRANSLOCATION; CARBOHYDRATE DIET; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DIETARY INTAKE; DYSBIOSIS; END STAGE RENAL DISEASE; ENTERITIS; FERMENTATION; GASTROINTESTINAL TRACT; HOST; HUMAN; IMMUNOREGULATION; INTESTINAL BARRIER; INTESTINE FLORA; INTESTINE FUNCTION; KIDNEY; KIDNEY GUT AXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DIET; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMBIOSIS; TOXIN SYNTHESIS; UREMIA; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; INTESTINE; MICROBIOLOGY; MICROFLORA; PATHOLOGY; RISK FACTOR;

CARDIOVASCULAR DISEASES; GASTROINTESTINAL TRACT; HUMANS; INTESTINES; MICROBIOTA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84939601831     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu287     Document Type: Review

References (92)

1. Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260-272
2. Gansevoort RT, Correa-Rotter R, Hemmelgam B et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanism and prevention. Lancet 2013; 382: 339-352
3. Carrero JJ, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: S49-S55
4. Szeto CC, Kwan BC, Chow KM et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008; 3: 431-436
5. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut and abnormal immunity in kidney disease. Kidney Int 2013; 83: 1010-1016
6. Baumgart DC, Dignass AU. Intestinal barrier function. Curr Opin Clin Nutr Metab Care 2002; 5: 685-694
7. Vaziri ND, Yuan J, Rahimi A et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012; 27: 2686-2693
8. Vaziri ND, Goshtasbi N, Yuan J et al. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol 2012; 36: 438-433
9. Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in CKD. Am J Nephrol 2013; 37: 1-6
10. Vaziri ND, Yuan J, Nazertehrani S et al. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 2013; 38: 99-103
11. Sekirov I, Russell SL, Caetano L et al. Gut microbiota in health and disease. Physiol Rev 2010; 90: 859-904
12. Arumugan N, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180
13. Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypert 2012; 21: 587-592
14. Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. JPEN J Parenter Enteral Nutr 1997; 21: 357-365
15. Scott KP, Gratz SW, Sheridan PO et al. The influence of diet in gut microbiota. Pharmacol Res 2012; 69: 52-60
16. Bäckhed F, Ley RE, Sonnenburg JL et al. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-1920
17. Evenepoel P, Meijers BKI, Bammens BRM et al. Uremic toxins originating from colonic microbial metabolism. Kidney Int 2009; 76: S12-S19
18. Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review. Altern Med Rev 2004; 9: 180-197
19. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 2014; 25: 657-670
20. Geuking MB, McCoy KD, Macpherson AJ. The function of secretory IgA in the context of the intestinal continuum of adaptive immune responses in host-microbial mutualism. Semin Immunol 2012; 24: 36-42
21. Swiatczak B, Rescigno M. How the interplay between antigen presenting cells and microbiota tunes host immune responses in the gut. Semin Immunol 2012; 24: 43-49
22. Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2009; 2: 403-411
23. Krishnamurthy VMR, Wei G, Baird BC et al. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 2012; 81: 300-306
24. Bammens B, Verbeke K, Vanrenterghem Y et al. Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 2003; 64: 2196-2203
25. Mafra D, Barros AF, Fouque D. Dietary protein metabolism by gut microbiota and its consequences for chronic kidney disease patients. Future Microbiol 2013; 8: 1317-1323
26. Nyangale EP, Mottram DS, Gibson GR. Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res 2012; 11: 5573-5585
27. Bammens B, Evenepoel P, Verbeke K et al. Impairment of small intestinal assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. Am J Clin Nutr 2004; 80: 1536-1543
28. Vaziri ND, Wong J, Pahl MV et al. Chronic kidney disease alters the composition of intestinal microbial flora. Kidney Int 2013; 83: 308-315
29. Wong J, Piceno YM, De Santis TZ et al. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD. Am J Nephrol 2014; 39: 230-237
30. Ritz E. Intestinal-renal syndrome: mirage or reality? Blood Purif 2011; 31: 70-76
31. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci 1993; 38: 257-268
32. Vaziri ND, Freel RW, Hatch M. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995; 6: 1313-1317
33. Koeth RA, Kalantar-Zadeh K, Wang Z et al. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol 2013; 24: 853-861
34. Apostolov EO, Basnakian AG, Ok E et al. Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease. J Ren Nutr 2012; 22: 134-138
35. Hatch M, Vaziri ND. Enhanced enteric excretion of urate in rats with chronic renal failure. Clin Sci 1994; 86: 511-516
36. Hatch M, Freel RW, Vaziri ND. Intestinal excretion of oxalate in chronic renal failure. J Am Soc Nephrol 1994; 5: 1339-1343
37. Neirynck N, Vanholder R, Schepers E et al. An update on uremic toxins. Int Urol Nephrol 2013; 45: 139-150
38. Sirich TL, Funk BA, Plummer NS et al. Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol 2014; 25: 615-622
39. Viaene L, Meijers BK, Bammens B et al. Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function. Perit Dial Int 2014; 34: 71-78
40. Dobre M, Meyer TW, Hostetter TH. Searching for uremic toxins. Clin J Am Soc Nephrol 2013; 8: 322-327
41. Meijers BK, Claes K, Bammens B et al. p-Cresol and cardiovascular risk in mild-to moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182-1189
42. Liabeuf S, Barreto DV, Barreto FC et al.Freep-cresyl sulfate is a predictor of mortality in patients in different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183-1191
43. Jourde-Chiche N, Dou L, Cerini C et al. Vascular incompetence in dialysis patients - protein-bound uremic toxins and endothelial dysfunction. Semin Dial 2011; 24: 327-337
44. Shunsuke I, Masayuki Y. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins 2014; 6: 665-678
45. Dou L, Jourde-Chiche N, Faure V et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007; 5: 1302-1308
46. Yu M, Kim YJ, Kang DH. Indoxyl sulfate induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011; 6: 30-39
47. Barreto FC, Barreto DV, Liabeuf S et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558
48. Rossi M, Campbell KL, Johnson DW et al. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 Chronic Kidney Disease. Arch Med Res 2014; 45: 309-317
49. Cerf-Bensussan N, Eberi G. The dialog between microbiota and the immune system: shaping the partners through development and evolution. Semin Immunol 2012; 24: 1-2
50. Molloy MJ, Bouladoux N, Belkaid Y. Intestinal microbiota: shaping local and systemic immune responses. Sem Immunol 2012; 24: 58-66
51. Mazmanian SK, Liu CH, Tzianabos AO et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122: 107-118
52. Lotz M, Guthe D, Walther S et al. Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. J Exp Med 2006; 203: 973-984
53. Dubuquoi L, Jansson EA. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003; 124: 1265-1276
54. Kumar A, Wu H, Collier-Hyams LS. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. EMBO J 2007; 26: 4457-4466
55. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007; 132: 1359-1374
56. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-241
57. Bode JG, Ehlting C, Häussinger D. The macrophage response towards LPS and its control through the p38 (MAPK)-STAT3 axis. Cell Signal 2012; 24: 1185-1194
58. Kieche S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192
59. Ryu M, Kulkarni OP, Radomska E. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte loss. Kidney Int 2011; 79: 189-198
60. Hauser AB, Stinghen AEM, Kato S et al. Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 2008; 28: S183-S187
61. Eleftheriadis T, Antoniadi G, Liakopoulos V et al. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007; 20: 440-451
62. Janus N, Vacher LV, Karie S et al. Vaccination and chronic kidney disease. Nephrol Dial Transplant 2008; 23: 800-807
63. Girndt M, Sester M, Sester U et al. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 2001; 78: S206-S201
64. Chow J. Probiotics and prebiotics: a brief overview. J Ren Nutr 2002; 12: 76-86
65. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 2008; 111: 1-66
66. Griffiths EA, Duffy LC, Schanbacher FL et al. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci 2004; 49: 579-589
67. Hida M, Aiba Y, Sawamura S et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355
68. Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 2003; 41: S142-S145
69. Ranganathan N, Friedman EA, Tam P et al. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6 months pilot scale trial in Canada. Curr Med Res Opin 2009; 25: 1919-1930
70. Ranganathan N, Ranganathan P, Friedman EA. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 2010; 27: 634-647
71. Alatriste PVM, Arronte RU, Espinosa COG et al. Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp 2014; 29: 582-590
72. Bliss DZ, Stein TP, Schleifer CR et al. Supplementation with gum Arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein-diet. Am J Clin Nutr 1996; 63: 392-398
73. Meyjers BK, Preter VD, Verbeke K et al. p-Cresyl sulfate serum concentrations in hemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010; 25: 219-224
74. Salmean YA, Segal MS, Langkamp-Henken B et al. Foods with added fiber lower serum creatinine levels in patients with chronic kidney disease. J Ren Nutr 2013; 23: e29-e32
75. Nakabayashi I, Nakamura M, Kawakami K et al. Effects of synbiotic treatment on serum level of p-cresol in hemodialysis patients: a preliminary study. Nephrol Dial Transplant 2011; 26: 1094-1098
76. Cruz-Mora J, Martínez-Hernández NE, del Campo-López FM et al. Effects of a symbiotic on gut microbiota in mexican patients with end-stage renal disease. J Ren Nutr 2014; 24: 330-335
77. Bass NM, Mullen KD, Sanyal A. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081
78. Poesen R, Meijers B, Evenepoel P. The colon: an overlooked site for therapeutics in dialysis patients. Sem Dial 2013; 26: 323-332
79. Evenepoel P, Bammens B, Verbeke K et al. Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: a pilot study. Kidney Int 2006; 70: 192-198
80. Goto S, Yoshiya K, Kita T et al. Uremic toxins and oral adsorbents. Ther Apher Dial 2011; 15: 132-134
81. Vaziri ND, Yuan J, Khazaeli M et al. Oral activated charcoal adsorbent (AST-120) ameliorates CKD-induced intestinal epithelial barrier disruption and systemic inflammation. Am J Nephrol 2013; 37: 518-525
82. Akizawa T, Asano Y, Morita S et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009; 54: 459-467
83. Shoji T, Wada A, Inoue K et al. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 2007; 105: c99-c107
84. Schulman G, Aqarwal R, Acharya M et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47: 565-577
85. Ueda J, Shibahara N, Takagi S et al. AST-120 treatment in pre-dialysis periods affects the prognosis in patients on hemodialysis. Ren Fail 2008; 30: 856-860
86. Stinghen AEM, Gonçalves SM, Bucharles S et al. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif 2010; 29: 352-356
87. Phan O, Ivanovski O, Nguyen-Khoa T et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112: 2875-2882
88. Brandenburg VM, Schlieper G, Heussen N et al. Serological cardio-vascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010; 25: 2672-2679
89. Meyer TW, Peattie JW, Miller JD et al. Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysis. J Am Soc Nephrol 2007; 18: 868-874
90. Meijers BK, Weber V, Bammens B et al. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs 2007; 32: 214-219
91. Krieter DH, Hackl A, Rodriguez A et al. Protein-bound uremic toxin removal in hemodialysis and post-dilution hemodiafiltration. Nephrol Dial Transplant 2010; 25: 212-218
92. Riccio E, Cataldi M, Minco M et al. Evidence that p-cresol and IL-6 are adsorbed by the HFR cartridge: towards a new strategy to decrease systemic inflammation in dialyzed patients? PLoS One 2014; 9: e95811